

Prof. İSMAIL ÇELİK

Personal Information

Email: cismail@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/cismail>

International Researcher IDs

ORCID: 0000-0003-1182-3865

Publons / Web Of Science ResearcherID: J-1229-2013

ScopusID: 17033620900

Yoksis Researcher ID: 18184

Education Information

Undergraduate, Hacettepe University, Tıp, Turkey 1982 - 1988

Foreign Languages

English, C1 Advanced

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic and Administrative Experience

Hacettepe Üniversitesi, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2014 - Continues

Hacettepe Üniversitesi, Kanser Enstitüsü, 2009 - 2013

Hacettepe Üniversitesi, Kanser Enstitüsü, Prevanatif Onkoloji Anabilim Dalı, 2004 - 2013

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy**
Karacin C., Eren T., Zeynelgil E., Imamoglu G. I., Altinbas M., Karadag I., Basal F. B., Bilgetekin I., SÜTCÜOĞLU O., YAZICI O., et al.
FUTURE ONCOLOGY, vol.17, pp.4447-4456, 2021 (SCI-Expanded)
- II. **Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches**
Karaca B. S., Sezer A., Goksu S. S., ÇİÇİN İ., Erdem D., ÇUBUKÇU E., Dane F., Hacibekiroglu I., Oksuzoglu B., Alnigenis E., et al.
JOURNAL OF TRANSLATIONAL MEDICINE, vol.19, 2021 (SCI-Expanded)
- III. **Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study**

Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., Sendur M. A. N., Sezer A., KILIÇKAP S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.267-272, 2020 (SCI-Expanded)

- IV. **Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study**
ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., Sendur M. A. N., Sezer A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1658-1664, 2019 (SCI-Expanded)
- V. **The role of ABO blood groups in glial neoplasms**
Alkan A., YAZICI G., CENGİZ M., Karakas Y., ÇELİK İ., Kars A., Zorlu F.
BRITISH JOURNAL OF NEUROSURGERY, vol.33, no.1, pp.43-46, 2019 (SCI-Expanded)
- VI. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**
HAYRAN K. M., Yuce D., Kilickap S., Dizdar O., Huseyin B., Erman M., Celik I.
VALUE IN HEALTH, vol.21, 2018 (SCI-Expanded)
- VII. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY AND RELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**
HAYRAN K. M., Yuce D., Kilickap S., Huseyin B., Erman M., Dizdar O., Celik I.
VALUE IN HEALTH, vol.21, 2018 (SCI-Expanded)
- VIII. **Reinforcement of mental health in an interaction group of cancer patients**
HAYRAN K. M., Kamisli S., Kucukcoban S., ÇELİK İ., KILIÇKAP S., YÜCE D.
PSYCHO-ONCOLOGY, vol.26, pp.161, 2017 (SCI-Expanded)
- IX. **Beneficiation routes for upgrading iron ore tailings with a teetered bed separator**
ÖZCAN Ö., ÇELİK İ.
SEPARATION SCIENCE AND TECHNOLOGY, vol.51, no.17, pp.2844-2855, 2016 (SCI-Expanded)
- X. **Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study**
Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., Oztop I., COŞKUN H. Ş., Turhal N. S., Sezer A., et al.
JOURNAL OF BUON, vol.20, no.4, pp.1137-1141, 2015 (SCI-Expanded)
- XI. **QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION**
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., ÇELİK İ.
VALUE IN HEALTH, vol.18, no.3, 2015 (SCI-Expanded)
- XII. **Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter**
Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.116, no.4, pp.354-360, 2015 (SCI-Expanded)
- XIII. **Nationwide Smoking Cessation Treatment Support Program - Turkey project**
ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., Irmak H., TOSUN N., Tuncer M., AKDAĞ R.
HEALTH POLICY, vol.119, no.1, pp.50-56, 2015 (SCI-Expanded)
- XIV. **HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION**
YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.
VALUE IN HEALTH, vol.17, no.7, 2014 (SCI-Expanded)
- XV. **ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS**
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., ÇELİK İ.
VALUE IN HEALTH, vol.17, no.7, 2014 (SCI-Expanded)
- XVI. **Study of interaction with a group of cancer patients: guiding cancer patients through psychoeducational interventions**
Kamisli S., HAYRAN K. M., Kucukcoban S., KILIÇKAP S., YÜCE D., ÇELİK İ.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.18, 2014 (SCI-Expanded)
- XVII. **Increasing performance of a hospital-based cancer registry: Hacettepe University hospitals experience**
Kutluk T., HAYRAN K. M., Kilickap S., Yuce D., Celik I., Erman M., Yalcin S.

JOURNAL OF BUON, vol.18, no.4, pp.1088-1096, 2013 (SCI-Expanded)

- XVIII. **Mass Balance and Quantitative Mineralogy Studies for Circuit Modification**
CAN N. M., ÇELİK İ., Bıçak Ö., Altun O.
MINERAL PROCESSING AND EXTRACTIVE METALLURGY REVIEW, vol.34, no.5, pp.348-365, 2013 (SCI-Expanded)
- XIX. **Multicentric Ipilimumab Experience in Turkish Patients with Metastatic Melanoma: MIPI-TURK at 3 years**
Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., Akbulut H., Celik I.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, vol.11, pp.68-69, 2013 (SCI-Expanded)
- XX. **Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience**
KILIÇKAP S., BARIŞTA İ., ÜLGER Ş., ÇELİK İ., SELEK U., YILDIZ F., Kars A., Ozisik Y., Tekuzman G.
BALKAN MEDICAL JOURNAL, vol.30, no.2, pp.178-185, 2013 (SCI-Expanded)
- XXI. **Bilateral Sequential Acral Lentiginous Melanoma of the Sole**
Keskin O., ÇELİK İ., KARS S. A.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.4, pp.276-277, 2013 (SCI-Expanded)
- XXII. **Long-term complications in Hodgkin's lymphoma survivors**
KILIÇKAP S., BARIŞTA İ., Ulger S., ÇELİK İ., SELEK U., Gullu I., YILDIZ F., Kars A., Ozisik Y., Tekuzman G.
TUMORI, vol.98, no.5, pp.601-606, 2012 (SCI-Expanded)
- XXIII. **Frequency of comorbid illnesses in cancer patients in Turkey**
Abali H., Ata A., Ozdogan M., Turhal S., Cabuk D., Seyrek E., COŞKUN H. Ş., Arik Z., Erman M., Celik I.
JOURNAL OF BUON, vol.16, no.3, pp.557-560, 2011 (SCI-Expanded)
- XXIV. **Influence of Process Mineralogy on Improving Metallurgical Performance of a Flotation Plant**
ÇELİK İ., CAN N. M., Sherazadishvili J.
MINERAL PROCESSING AND EXTRACTIVE METALLURGY REVIEW, vol.32, no.1, pp.30-46, 2011 (SCI-Expanded)
- XXV. **FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS**
Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., Kutluk T.
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGİSİ, vol.14, no.3, pp.187-192, 2011 (SCI-Expanded)
- XXVI. **Arsenic in drinking water and lung cancer: A systematic review**
ÇELİK İ., Gallicchio L., Boyd K., Lam T. K., Matanoski G., Tao X., Shiels M., Hammond E., Chen L., Robinson K. A., et al.
ENVIRONMENTAL RESEARCH, vol.108, no.1, pp.48-55, 2008 (SCI-Expanded)
- XXVII. **Prognostic impact of bone turnover markers in multiple myeloma**
Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Hascelik G., Cila A., Pinar A., Tekuzman G.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- XXVIII. **Erectile dysfunction in successfully treated lymphoma patients**
AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., Ozen H., ERMAN M., ÇELİK İ.
SUPPORTIVE CARE IN CANCER, vol.16, no.3, pp.291-297, 2008 (SCI-Expanded)
- XXIX. **Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: A comparison of efficacy, side-effect profile, and cost**
Abali H., Celik I.
CANCER INVESTIGATION, vol.25, no.3, pp.135-139, 2007 (SCI-Expanded)
- XXX. **L-2-hydroxyglutaric aciduria and brain tumors: Report of two patients with medulloblastoma and glioblastoma**
Haliloglu G., Celik I., Karli O. K., Anlar B., Ozisik P., Akalan N., Soylemezoglu F., Sass J. O., Coskun T., Fischer J., et al.
JOURNAL OF INHERITED METABOLIC DISEASE, vol.29, pp.53, 2006 (SCI-Expanded)
- XXXI. **Acrocyanosis as a presenting symptom of Hodgkin lymphoma**
Solak Y., Aksoy S., Kilickap S., Celik I.
AMERICAN JOURNAL OF HEMATOLOGY, vol.81, no.2, pp.151-152, 2006 (SCI-Expanded)
- XXXII. **Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists**
Babaoglu M., Bayar B., Aynacioglu A., Kerb R., Abali H., Celik I., Bozkurt A.

- CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.78, no.6, pp.619-626, 2005 (SCI-Expanded)
- XXXIII. **Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis**
Guler N., Uckan S., Celik I., Oznurlu Y., Uckan D.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol.34, no.8, pp.900-906, 2005 (SCI-Expanded)
- XXXIV. **cTnT can be a useful marker for early detection of anthracycline cardiotoxicity**
Kilickap S., Baristal I., Akgul E., Aytemir K., Aksoyek S., Aksoy S., Celik I., Kes S., Tekuzman G.
ANNALS OF ONCOLOGY, vol.16, no.5, pp.798-804, 2005 (SCI-Expanded)
- XXXV. **Cytarabine-induced fever complicating the clinical course of leukemia**
GÖNEN C., Celik I., Cetinkaya Y., Haznedaroglu I.
ANTI-CANCER DRUGS, vol.16, no.1, pp.59-62, 2005 (SCI-Expanded)
- XXXVI. **CA 19-9 measurement as a screening: Higher cost, lower survival**
Kilickap S., Abali H., Aksoy S., Celik I.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.19, no.12, pp.1428, 2004 (SCI-Expanded)
- XXXVII. **Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?**
Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KIRAZLI Ş., Celik I.
ANNALS OF ONCOLOGY, vol.15, no.11, pp.1622-1626, 2004 (SCI-Expanded)
- XXXVIII. **Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia**
Altundag O., Altundag K., Celik I., Turker A., Kars A.
AMERICAN JOURNAL OF HEMATOLOGY, vol.75, no.4, pp.263-264, 2004 (SCI-Expanded)
- XXXIX. **Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet's disease**
Ozturk M., Ertenli I., Kiraz S., Haznedaroglu I., Celik I., Kirazli S., Calguneri M.
RHEUMATOLOGY INTERNATIONAL, vol.24, no.2, pp.98-102, 2004 (SCI-Expanded)
- XL. **Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women - A case-control study**
ORAN B., Celik I., Erman M., BALTALI E., ZENGİN N., Demirkazik F., TEZCAN S.
MEDICAL ONCOLOGY, vol.21, no.1, pp.31-39, 2004 (SCI-Expanded)
- XLI. **Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer**
Yalcin S., Oksuzoglu B., Tekuzman G., Engin H., Celik I., Turker A., Barista I., Gullu I., Guler N., Altundag K., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.11, pp.580-583, 2003 (SCI-Expanded)
- XLII. **The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis**
Calguneri M., Apras S., Ozbalkan Z., Ertenli I., Kiraz S., Ozturk M., Celik I.
CLINICAL RHEUMATOLOGY, vol.22, pp.289-294, 2003 (SCI-Expanded)
- XLIII. **Bevacizumab, bleeding, thrombosis, and warfarin**
Kilickap S., Abali H., Celik I.
JOURNAL OF CLINICAL ONCOLOGY, vol.21, no.18, pp.3542, 2003 (SCI-Expanded)
- XLIV. **Pathologic thrombopoiesis of rheumatoid arthritis**
Ertenli I., Kiraz S., Ozturk M., Haznedaroglu I., Celik I., Calguneri M.
RHEUMATOLOGY INTERNATIONAL, vol.23, no.2, pp.49-60, 2003 (SCI-Expanded)
- XLV. **Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors**
Karaoglu A., Yalcin S., Tekuzman G., Kars A., Celik I., Guler N., Ozisik Y., Turker A., Barista I., Gullu I.
TUMORI, vol.89, no.2, pp.141-145, 2003 (SCI-Expanded)
- XLVI. **Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis**
Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Calguneri M., Atalar E., Ozbalkan Z., Kirazli S., Celik I.

JOURNAL OF RHEUMATOLOGY, vol.30, no.2, pp.313-315, 2003 (SCI-Expanded)

- XLVII. **Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients**
Ozturk M., Barista I., Altundag M., Turker A., Yalcin S., Celik I., Gullu I., Guler N., Ozisik Y., Kars A., et al.
CHEMOTHERAPY, vol.48, no.5, pp.252-258, 2002 (SCI-Expanded)
- XLVIII. **High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel**
Abali H., Celik I.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.25, no.6, pp.632-633, 2002 (SCI-Expanded)
- XLIX. **Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: A preliminary report**
Baltahi E., Altundag M., Onat D., Abbasoglu O., Ozisik Y., Guler N., Atahan L., Berberoglu U., Altinok M., Baran I., et al.
TUMORI J, vol.88, no.6, pp.474-477, 2002 (SCI-Expanded)
- L. **Bloodstream thrombopoietin in rheumatoid arthritis with thrombocytosis**
Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Celik I., Kirazli S., Calguneri M.
CLINICAL RHEUMATOLOGY, vol.21, no.6, pp.453-456, 2002 (SCI-Expanded)
- LI. **Treatment of classical Kaposi's sarcoma with visceral involvement by weekly paclitaxel**
Engin H., Celik I.
CLINICAL ONCOLOGY, vol.14, no.2, pp.178, 2002 (SCI-Expanded)
- LII. **Pineal germ cell tumor metastasis via ventriculoperitoneal shunt**
Altundag O., Celik I., Kars A.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.25, no.1, pp.104-105, 2002 (SCI-Expanded)
- LIII. **Pathological haemostasis and 'prothrombotic state' in Behcet's disease**
Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Celik I., Calguneri M.
THROMBOSIS RESEARCH, vol.105, no.2, pp.125-133, 2002 (SCI-Expanded)
- LIV. **Dihydropyrimidine dehydrogenase enzyme deficiency: Clinical and genetic assessment of prevalence in Turkish cancer patients**
Celik I., Kars A., Guc D., Tekuzman G., Ruacan S.
CANCER INVESTIGATION, vol.20, no.3, pp.333-339, 2002 (SCI-Expanded)
- LV. **Central nervous system bleeding as a first manifestation of immunothrombocytopenic purpura in Hodgkin's disease**
Engin H., Abali H., Erman M., Karaoglu A., Celik I., Guler N.
HAEMATOLOGIA, vol.31, no.4, pp.373-375, 2002 (SCI-Expanded)
- LVI. **2,2-exo-3,5,6-Pentabromobicycloheptane**
Hokelek T., Celik I., TUTAR A., CAKMAK O.
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, vol.57, 2001 (SCI-Expanded)
- LVII. **Crystal structure of 2,2-exo-3,5,5-exo-6-hexabromobicycloheptane, C₇H₆Br₆**
Akkurt M., Celik I., Tutar A., Cakmak O., Ide S.
ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES, vol.215, no.4, pp.529-530, 2000 (SCI-Expanded)
- LVIII. **Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy**
Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., Ozisik Y., Kars A., Celik I., Turker A., Altundag K., et al.
JOURNAL OF SURGICAL ONCOLOGY, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded)
- LIX. **Crystal structure of 7-acetyl-5-benzoyl-6-phenyl-8-methyl-4,7-dihydropyrazolo[1,5-c]-1 H-pyrimidine-2-one**
Celik I., Akkurt M., Ide S., Onal Z., Altural B.
ZEITSCHRIFT FUR KRISTALLOGRAPHIE, vol.215, no.1, pp.48-51, 2000 (SCI-Expanded)
- LX. **Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever**

Articles Published in Other Journals

- I. **Smoker Relatives of Inpatients: A Reasonable but Heterogeneous Target Population for Smoking Cessation Program**
AKTAŞ B. Y., HÜSEYİN B., YÜCE D., DİZDAR Ö., ERMAN M., HAYRAN M., CELİK İ.
Archives of Basic and Clinical Research, vol.5, no.1, pp.178-184, 2023 (Peer-Reviewed Journal)
- II. **BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ**
KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., ERMAN M.
Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi, vol.20, no.4, pp.234-242, 2017 (Peer-Reviewed Journal)
- III. **A Retrospective Study of 137 Dysplastic Nevi Are a Personal History of Melanoma and Histopathological Factors Associated with High grade Cytologic Atypia**
DUMAN N., ERKİN G., GÖKÖZ Ö., KARAHAN S., KAYIKÇIOĞLU A. U., ÇELİK İ.
Journal of Cancer and Tumor International, vol.2, no.3, pp.110-116, 2015 (Peer-Reviewed Journal)
- IV. **Nevus-Associated versus de novo Melanoma: Do They Have Different Characteristics and Prognoses?**
Duman N., Erkin G., GÖKÖZ Ö., KARAHAN S., Kayikcioglu A. U., ÇELİK İ.
DERMATOPATHOLOGY, vol.2, no.1, pp.46-51, 2015 (ESCI)
- V. **A Rare Variant of Melanoma Clinical Histopathological and Prognostic Features in 5 Cases of Animal Type Melanoma**
DUMAN N., ERKİN G., GÖKÖZ Ö., KAYIKÇIOĞLU A. U., ÇELİK İ.
ACTA ONCOLOGICA TURCICA, vol.47, no.3, pp.20-25, 2014 (Peer-Reviewed Journal)
- VI. **Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature**
Tapan U., DİZDAR Ö., Bulut N., ÇELİK İ.
EURASIAN JOURNAL OF MEDICINE, vol.43, no.3, pp.189-191, 2011 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **HACETTEPE'DE MELANOM TANISI ALAN HASTALARIN DEĞERLENDİRİLMESİ: 321 HASTAYA AİT RETROSPEKTİF TANIMLAYICI ÇALIŞMA**
AKDOĞAN N., ELÇİN G., GÖKÖZ Ö., KONAŞ E., KILIÇKAP S., ÇELİK İ.
8. Ulusal Dermatolojik Cerrahi Günleri, Ankara, Turkey, 18 November 2021
- II. **BİR ÜNİVERSİTENİN SİGARA BIRAKMA ÜNİTESİNE BAŞVURANLARIN ÖZELLİKLERİ VE SİGARA BIRAKMA OLASILIKLARI**
ŞENGELEN M., ÇELİK İ., ERMAN M., Tezcan S., YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN Ş., HAYRAN K. M.
2. ULUSLARARASI 20. ULUSAL HALK SAĞLIĞI KONGRESİ, Antalya, Turkey, 13 - 17 November 2018
- III. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**
HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., ÇELİK İ.
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018
- IV. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**
HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., ÇELİK İ.
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, vol.1, pp.11
- V. **Metastatic Choroidal Melanoma: Single Center Experience**
AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., KILIÇKAP S., ÇELİK İ.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48

- VI. **Reinforcement of mental health in an interaction group of cancer patients**
HAYRAN K. M., KAMIŞLI S., KÜÇÜKÇOBAN Ş., ÇELİK İ., KILIÇKAP S., YÜCE D.
2017 World Congress of Psycho-Oncology, 14 - 18 August 2017
- VII. **Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic**
YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN Ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., ERMAN M.
2017 World Congress of Psycho-Oncology, 14 - 18 August 2017
- VIII. **Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program**
AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., HAYRAN K. M., ÇELİK İ.
7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017
- IX. **The role of ABO blood groups in glial neoplasia**
Alkan A., Yazici G., Cengiz M., Celik I., Kars A., Zorlu F.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- X. **Using geographical information systems to describe quality of life as a function of distance in cancer patients**
HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., ÇELİK İ.
ISPOR Asia Pacific Meeting 2016, 3 - 06 September 2016, vol.19, pp.892
- XI. **Imaging the interactions between oral pathogens and probiotic lactic acid bacteria on the adhesion to human gingival fibroblast cells by confocal and fluorescein microscopy**
Akca G., Celik I., Ermis M., Foto E.
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.110-111
- XII. **ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B INFECTION PATIENTS IN TURKEY: A MULTICENTER STUDY**
Karacaer Z., Cakir B., Erdem H., Ugurlu K., Durmus G., Ince N. K., Ozturk C., Batirel A., Yilmaz E. M., Bozkurt I., et al.
EASL International Liver Congress, Barcelona, Spain, 13 - 17 April 2016, vol.64
- XIII. **Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study**
Urun Y., Abali H., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N. Y., Sendur M. A. N., Sezer A., et al.
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- XIV. **The survival rate at 5 years in Turkish metastatic melanoma patients treated with ipilimumab: Final analysis of MIPI-TURK**
Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Mandel N. M., Demir G., Gokmen E., Paydas S., Akbulut H., Celik I.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey**
Celik I., Mandel N. M., Gokmen E., Unal O. U., Sevinc A., Coskun H. S., Buyukberber S., Abali H., Ozguroglu M., Utkan G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XVI. **Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up.**
Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., Akbulut H., Celik I.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

- XVII. **Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.**
Sevinc A., TURNA Z. H., Ozdogan M., Buyukberber S., Demir G., Gokmen E., Mandel N. M., Paydas S., Akbulut H., Celik I.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XVIII. **MIPI-TURK - Multicentric Ipilimumab Experience in Turkish Patients With Metastatic Melanoma**
Sevinc A., Ozdogan M., Buyukberber S., Aydin F., Mandel N. M., Demir O. G., Gokmen E., Arpacı F., Paydas S., Celik I.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- XIX. **Relationship between genetic polymorphisms of multidrug resistance gene MDR1 (ABCB1) and clearance of 99mTc-MIBI**
Kapulu-Akca C., Goktas M., Babaoglu M. O., Altundag K., Yasar U., Celik I., Bozkurt A., Erbas B.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37
- XX. **Frequency of co-morbid illnesses in cancer patients in Turkey**
Abali H., Ata A., Turhal S., Ozdogan M., Seyrek E., Erman M., Celik I.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XXI. **Gastric cancer in Turkey: Characteristics and etiology (a case control study of Turkish Oncology Group)**
Icli F., Yalcin B., Ozdemir F., Isikdogan A., Celik I., Unsal D., Coskun S., Abdullah B., Yamac D.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.324
- XXII. **Biochemical markers of bone turnover in the diagnosis of myeloma bone disease.**
Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Tekuzman G.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXIII. **Increased Troponin-T level is associated with anthracycline-induced diastolic dysfunction of the left ventricle.**
Kilickap S., Barista I., Akgul E., Aytemir K., Aksoyek S., Celik I., Kes S., Tekuzman G.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Supported Projects

HAYRAN K. M., KILIÇKAP S., KAMIŞLI S., YÜCE D., ÇELİK İ., KÜÇÜKÇOBAN Ş., Project Supported by Higher Education Institutions, Etkileşim Gruplarında Kanser Hastalarının Başetmeleri, 2015 - 2016

Metrics

Publication: 89

Citation (WoS): 969

Citation (Scopus): 228

H-Index (WoS): 14

H-Index (Scopus): 9

Non Academic Experience

Johns Hopkins University, Baltimore, USA